NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $842,476 | +37.9% | 23,305 | +51.1% | 0.00% | 0.0% |
| Q4 2022 | $610,751 | -79.8% | 15,423 | -76.3% | 0.00% | -78.9% |
| Q3 2022 | $3,031,000 | -23.2% | 65,037 | -27.8% | 0.02% | -20.8% |
| Q2 2022 | $3,949,000 | +52.2% | 90,094 | +151.1% | 0.02% | +71.4% |
| Q1 2022 | $2,595,000 | -41.2% | 35,875 | -34.1% | 0.01% | -39.1% |
| Q4 2021 | $4,412,000 | -76.8% | 54,419 | -66.6% | 0.02% | -77.7% |
| Q3 2021 | $18,986,000 | -54.4% | 163,142 | -35.0% | 0.10% | -56.2% |
| Q2 2021 | $41,632,000 | +17.5% | 251,113 | -1.1% | 0.24% | +5.9% |
| Q1 2021 | $35,435,000 | +15.4% | 254,017 | +43.2% | 0.22% | +14.4% |
| Q4 2020 | $30,715,000 | -26.3% | 177,440 | -40.7% | 0.19% | -38.8% |
| Q3 2020 | $41,672,000 | +8.3% | 299,152 | -7.1% | 0.32% | -5.9% |
| Q2 2020 | $38,485,000 | +115.4% | 322,131 | +80.3% | 0.34% | +75.5% |
| Q1 2020 | $17,863,000 | +2627.2% | 178,662 | +1454.8% | 0.19% | +1645.5% |
| Q3 2018 | $655,000 | +110.6% | 11,491 | +194.6% | 0.01% | +57.1% |
| Q2 2018 | $311,000 | – | 3,901 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |